The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Microbot Medical is transitioning from R&D to commercialization with its LIBERTY single-use robotic system for endovascular interventions. I assign MBOT a neutral rating with a 1-year price target of ...
Robotics is a fascinating field that has come a long way in recent years. What was once cutting-edge and prohibitively expensive for consumer-grade projects has rapidly become accessible to the hobby ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Fintel reports that on December 3, 2025, Roth Capital initiated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. As of November 17, 2025, the average one-year price target for ...
Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...
About 11 schools in Aurora receive robotics kits from the Department of Science and Technology, providing students with hands-on exposure to science, technology, engineering, and mathematics. (DOST) ...
THE Department of Science and Technology (DOST) distributed robotics kits amounting to P4.8 million to provide students in 11 schools in Aurora with hands-on exposure to science, technology, ...
We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...
MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...
Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a developer of the LIBERTY Endovascular Robotic System, is actively preparing for the system’s anticipated U.S. launch projected for the third ...